Association of the Apolipoprotein B Gene Polymorphisms with Cholesterol Levels and Response to Fluvastatin in Brazilian Individuals with High Risk for Coronary Heart Disease

• Published in: Clinical chemistry and laboratory medicine Vol. 38; no. 8; pp. 731 - 736
• Main Authors: Guzmán, Elizabeth C.R., Hirata, Mario H., Quintão, Éder C.R., Hirata, Rosario D.C.
• Format: Journal Article
• Language: English
• Published: Berlin Walter de Gruyter 21.08.2000; New York, NY
• Subjects: Adult; Aged; Anticholesteremic Agents - therapeutic use; Apolipoproteins B - blood; Apolipoproteins B - genetics; Biological and medical sciences; Brazil; Cardiology. Vascular system; Cholesterol - blood; Coronary Disease - blood; Coronary Disease - drug therapy; Coronary Disease - genetics; Coronary heart disease; European Continental Ancestry Group - genetics; Fatty Acids, Monounsaturated - therapeutic use; Female; Gene Frequency; General and cellular metabolism. Vitamins; Genotype; Heart; Humans; Indoles - therapeutic use; Lipids - blood; Lipoproteins - blood; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Polymorphism, Genetic; Risk Factors; South America; Brazil; America; Human; Pharmacogenetics; Enzyme; Treatment efficiency; Enzyme inhibitor; Cardiovascular disease; Metabolic diseases; Lipids; Hyperlipoproteinemia; Coronary heart disease; Genetic determinism; Apolipoprotein B; Chemotherapy; Fluvastatin; Hypercholesterolemia; Treatment; Risk factor; Genetics; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases; Dyslipemia; Antilipemic agent; Polymorphism
• ISSN: 1434-6621; 1437-4331
• DOI: 10.1515/CCLM.2000.103

The influence of genetic polymorphism of the apolipoprotein B on lipid metabolism and coronary heart disease (CHD) risk has been demonstrated in different populations, but few studies have shown the contribution of this risk factor in individuals from Brazil. The Ins/del, XbaI and EcoRI polymorphisms of apo B were evaluated in 93 controls and in 104 Caucasian individuals presenting with a high risk lipid profile (HR1) for CHD; 54 of these subjects (HR2) were treated with fluvastatin during 16 weeks. DNA polymorphisms of the apo B gene were analyzed by polymerase chain reaction–restriction fragment length polymorphism. The X(−)X(−) genotype for XbaI polymorphism was associated with higher serum concentrations of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) (p<0.01) in women of the HR1 group. The Ins/del and EcoRI polymorphisms were not associated with variation of lipid profile. After treatment with fluvastatin, TC and LDL-C levels of HR2 individuals were reduced by 23% and 30%, respectively. Individuals with II genotype had significantly greater reduction (34%) of LDL-C than those with ID/DD genotypes (27%). These results indicate that the XbaI polymorphism is associated with variation of serum TC and LDL-C levels in Brazilian women with lipid profile of risk for CHD and the Ins/del polymorphism is associated with the therapeutic response to fluvastatin.